Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The PPT2-EGFL8 locus represents a read-through transcript between the palmitoyl-protein thioesterase 2 (PPT2) and EGF-like domain multiple 8 (EGFL8) genes, found within the major histocompatibility complex region on chromosome 6. This transcript is classified as a nonsense-mediated decay (NMD) candidate and is generally not thought to produce a functional protein product[3][7]. The fusion gene has been implicated in rare genetic disorders with developmental abnormalities and intellectual disability, possibly through the unique structure combining the phosphatase domain of PPT2 with an EGFL8 domain[1]. However, its precise biological function and clinical significance remain largely hypothetical, with most functional disease data attributed to PPT2 itself, a lysosomal enzyme involved in palmitoyl-CoA hydrolysis and lipid metabolism[2][5][8]. PPT2 deficiency leads to neurodegenerative disorders in model organisms, but the PPT2-EGFL8 fusion transcript has limited direct clinical or therapeutic characterization.
None established for this transcript. For PPT2 enzyme: palmitoyl-CoA hydrolysis by lysosomal thioesterase mechanism
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PPT2-EGFL8 readthrough (PPT2-EGFL8).